IMPaCT-GENóMICA realiza la secuenciación del genoma completo a las personas que acceden al programa tras no haber obtenido el diagnóstico con las pruebas asistenciales habituales. Con herramientas ...
Read moreResearchers from Clínic-IDIBAPS, within the Clínic Barcelona Comprehensive Cancer Center, and the spin-off Gyala Therapeutics have coordinated a study demonstrating the efficacy of CAR-T GYA01 thera...
Read moreUn equipo liderado por Núria Malats, del Centro Nacional de Investigaciones Oncológicas (CNIO), ha desarrollado un algoritmo que predice con precisión la existencia de metástasis a partir de imág...
Read moreOryzon Genomics, S.A. a clinical-stage biopharmaceutical company and a European leader in epigenetics, today announced that it continues to expand its patent portfolio for iadademstat and vafidemstat,...
Read moreThe findings suggest that inhibiting CNNM4, combined with GalNAc siRNA technology, could offer a targeted, safe, and effective treatment, opening new avenues for personalized therapies against this ag...
Read moreHighlight Therapeutics is a Spanish biotechnology company specialising in immuno-oncology, focused on the development of innovative cancer therapies. Its lead investigational compound, BO-112, is a do...
Read moreEs el primer centro de Cataluña que utiliza el tratamiento con un radioisótopo (Re-188) para tratar este tipo de lesión. Se trata de una técnica no invasiva, que puede permitir evitar el abordaje ...
Read moreThe Office of knowledge and Technology Transfer of the University of Navarra defends the need to adopt a clinical research model that connects the detection of medical needs with innovative solutions ...
Read moreEl estudio sugiere actuar sobre el entorno del tumor, como alternativa a los tratamientos actuales que atacan directamente a las células tumorales
Read moreA research group from the National Cancer Research Centre (CNIO) has found that an alteration in the POT1 gene prevents lung tissue from regenerating, which over time makes breathing difficult.
Read moreBatea Oncology has developed GlioHook, an innovative medical device implanted during surgery that captures residual tumor cells responsible for relapse and makes them more sensitive to standard radiot...
Read moreThe study demonstrates how the MAF Test®, which stratifies early-stage breast cancer patients by MAF gene status to guide adjuvant bisphosphonate therapy, delivers meaningful economic value across mu...
Read more